Stelara, known generically as ustekinumab, is a medication used to treat autoimmune conditions such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis [1]. Its active ingredient, ustekinumab, is a human monoclonal antibody that targets the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23) [1][2]. These cytokines play a role in inflammatory processes [2].
When does Stelara's patent protection end?
The patent landscape for Stelara is complex, involving multiple patents covering the drug substance, methods of use, and manufacturing processes [3]. DrugPatentWatch.com tracks these patents, and their expiry dates vary [3]. Generally, primary patents for innovative drugs like Stelara begin to expire, opening the door for generic or biosimilar competition, though the exact timing can be influenced by various legal and regulatory factors [3][4]. For specific details on Stelara's patent expiry timeline, consulting resources like DrugPatentWatch.com is recommended [3].
What are the main patents protecting Stelara?
Stelara is protected by a portfolio of patents. These include patents related to the ustekinumab molecule itself, as well as patents covering its use in treating specific diseases and methods for its production [3]. The expiration of these key patents is a critical event for the market, as it signals the potential for alternative versions of the drug to become available [4].
Can generic or biosimilar versions of Stelara be developed?
Yes, the development of generic and biosimilar versions of Stelara is possible once the relevant patents expire and other market exclusivities lapse [4]. For biologics like Stelara, the alternative to a generic is a biosimilar, which is a highly similar but not identical copy of the original biologic drug [5]. The development and approval process for biosimilars is rigorous, ensuring they meet standards of safety and efficacy [5].
What is the difference between a generic drug and a biosimilar?
Generic drugs are exact copies of small-molecule drugs, meaning they have the same active ingredient, dosage form, strength, and route of administration. Biosimilars, on the other hand, are for biologic drugs, which are complex molecules derived from living organisms. While a biosimilar is highly similar to its reference biologic product and has no clinically meaningful differences in terms of safety, purity, and potency, it is not an exact replica due to the inherent complexity of biologic manufacturing [5].
What companies are developing biosimilars for Stelara?
Several pharmaceutical companies are actively involved in developing biosimilars for Stelara. These include companies such as Amgen, Samsung Bioepis, and Alvotech, among others [6][7]. The successful development and approval of these biosimilars could lead to increased competition and potentially lower prices for ustekinumab [4][7].
What is the regulatory pathway for Stelara biosimilars?
In the United States, biosimilars are regulated by the Food and Drug Administration (FDA) under the Biologics Price Competition and Innovation Act (BPCIA) [5]. Developers must demonstrate that their biosimilar is highly similar to the reference product and that there are no significant clinical differences in safety, purity, and potency [5]. Similar pathways exist in other regions, such as through the European Medicines Agency (EMA) [8].
What is the clinical data supporting Stelara's efficacy and safety?
Stelara has demonstrated significant efficacy and a generally favorable safety profile across its approved indications. Clinical trials have shown substantial improvements in disease activity and quality of life for patients with plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis [1][9]. Common side effects reported include upper respiratory infections, headache, fatigue, and injection site reactions [1]. Serious side effects are rare but can include infections and certain types of cancer [1].
How does Stelara compare to other treatments for autoimmune diseases?
Stelara's mechanism of action, targeting IL-12 and IL-23, differentiates it from other biologics that target different inflammatory pathways, such as TNF inhibitors (e.g., adalimumab, infliximab) or IL-17 inhibitors [2][10]. Patient response can vary, and factors such as disease severity, prior treatment history, and individual patient characteristics influence treatment selection [10]. Comparative effectiveness research helps guide clinicians in choosing the most appropriate therapy for each patient [10].
Sources:
[1] https://www.janssen.com/us/our-products/ Stelara
[2] https://www.drugbank.ca/drugs/DB00709
[3] https://drugpatentwatch.com/
[4] https://www.fda.gov/drugs/generic-drugs/what-generic-drugs
[5] https://www.fda.gov/vaccines-blood-biologics/biosimilars/what-biosimilar-
[6] https://www.fiercepharma.com/pharma/amgen-s- Stelara-biosimilar-gets-fda-nod-first-major-hurdle-cleared-for-blockbuster-drug
[7] https://www.biosimlarity.org/news/alvotech-reports-positive-topline-results- ustekinumab-biosimilar-phase-3-trial
[8] https://www.ema.europa.eu/en/human-regulatory/overview/pathways-medicines-evaluation/biosimilar-medicines
[9] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414835/
[10] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925121/